Shanghai Haihe Pharmaceutical Co., Ltd from China and its South Korean partner Daehwa Pharmaceutical have received approval from the National Medical Products Administration (NMPA) for their co-developed paclitaxel oral solution RMX3001. This new drug is intended for use in patients with advanced gastric cancer who have experienced disease progression during or after first-line treatments that are based on fluorouracil regimens.
RMX3001, recognized as the world’s first oral paclitaxel, has already been approved to treat second-line gastric cancer in South Korea, following the successful demonstration of its efficacy in the Phase III DREAM study conducted there. With this approval, RMX3001 also becomes the first oral paclitaxel of its kind to be approved in China.- Flcube.com
